DAVENPORT & Co LLC Purchases Shares of 15,524 Prestige Consumer Healthcare Inc. (NYSE:PBH)

DAVENPORT & Co LLC acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,524 shares of the company's stock, valued at approximately $1,212,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PBH. JPMorgan Chase & Co. lifted its stake in Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock valued at $19,630,000 after buying an additional 8,533 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock valued at $95,678,000 after acquiring an additional 50,961 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock valued at $708,000 after acquiring an additional 1,120 shares in the last quarter. Avior Wealth Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock worth $668,000 after acquiring an additional 8,042 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company's stock worth $6,665,000 after purchasing an additional 71,730 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Up 0.3 %

Shares of PBH traded up $0.29 during mid-day trading on Monday, reaching $87.29. The stock had a trading volume of 397,000 shares, compared to its average volume of 318,635. Prestige Consumer Healthcare Inc. has a 52-week low of $62.35 and a 52-week high of $88.36. The firm has a market cap of $4.31 billion, a price-to-earnings ratio of 20.44, a P/E/G ratio of 2.43 and a beta of 0.50. The business's fifty day moving average is $79.23 and its 200 day moving average is $75.51. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company's stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares in the company, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last quarter. 1.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Canaccord Genuity Group raised their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday. StockNews.com raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday, January 24th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Finally, DA Davidson boosted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $92.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.